Vivus stock rises as US FDA says it will review obesity drug candidate Qnexa

29 March 2010

The news that an advisory committee of the USA's Food and Drug Adminstration is set to review California-based drugmaker Vivus' New Drug Application (NDA) for Qnexa (phentermine plus topamax), for the treatment of obesity on July 15 saw the firm's share price rise 1.6% to $9.51 in late morning trading last Friday, having increased 14% and in the past month.

Vivus submitted its NDA on December 28, 2009 seeking approval to market Qnexa in theUSA; on March 1 this year, the agency accepted the NDA filing for review and the target date to complete its review is October 28.

"Review by the Advisory Committee represents a critical milestone for Qnexa and for Vivus. We believe Qnexa, if approved, could become a treatment option for obese patients," stated Leland Wilson, chief executive of Vivus

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK